(TVTX) Travere Therapeutics - Ratings and Ratios
Kidney Drug, Rare Disease Therapy
TVTX EPS (Earnings per Share)
TVTX Revenue
Description: TVTX Travere Therapeutics
Travere Therapeutics Inc (NASDAQ:TVTX) is a biotechnology company listed on the NASDAQ exchange. The companys stock is classified under the GICS Sub Industry: Biotechnology, indicating its primary focus is on developing and commercializing biotechnological products.
From a technical analysis perspective, the stock is currently trading at $17.28, with key resistance levels identified at $21.1, $20.0, and $17.4, and a support level at $13.4. The stocks moving averages indicate a potential bullish trend, with the 20-day SMA at $16.15 and the 50-day SMA at $15.52, both below the current price.
The companys market capitalization stands at $1.388 billion, indicating a moderate to large-cap stock. The absence of a P/E ratio and forward P/E ratio suggests that the company is currently not profitable or has negative earnings. Key economic drivers for Travere Therapeutics include the success of its pipeline products, particularly in the rare disease space, and the overall demand for its commercialized products.
To evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, R&D expenses as a percentage of revenue, and cash burn rate should be closely monitored. The companys ability to advance its pipeline products through clinical trials and obtain regulatory approvals will be crucial in driving future revenue growth. Additionally, the competitive landscape of the biotechnology industry, particularly in the rare disease space, will impact Travere Therapeutics market share and pricing power.
The stocks beta of 0.725 indicates relatively lower volatility compared to the overall market, suggesting that it may be a relatively stable investment option for investors seeking exposure to the biotechnology sector. However, investors should be cautious of the companys negative earnings and closely monitor its progress in advancing its pipeline products and achieving profitability.
TVTX Stock Overview
| Market Cap in USD | 2,434m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2012-11-08 |
TVTX Stock Ratings
| Growth Rating | -8.90% |
| Fundamental | 29.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 35.6% |
| Analyst Rating | 4.60 of 5 |
TVTX Dividends
Currently no dividends paidTVTX Growth Ratios
| Growth Correlation 3m | 92.5% |
| Growth Correlation 12m | -2.3% |
| Growth Correlation 5y | -58.8% |
| CAGR 5y | -4.71% |
| CAGR/Max DD 3y | -0.06 |
| CAGR/Mean DD 3y | -0.12 |
| Sharpe Ratio 12m | -0.06 |
| Alpha | 74.21 |
| Beta | 0.581 |
| Volatility | 127.93% |
| Current Volume | 2223.2k |
| Average Volume 20d | 1961.8k |
| Stop Loss | 21.4 (-7%) |
| Signal | -0.50 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-169.1m TTM) > 0 and > 6% of Revenue (6% = 20.0m TTM) |
| FCFTA -0.61 (>2.0%) and ΔFCFTA -2.51pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 56.92% (prev 139.4%; Δ -82.52pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.21 (>3.0%) and CFO -115.4m > Net Income -169.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.00 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (88.9m) change vs 12m ago 14.77% (target <= -2.0% for YES) |
| Gross Margin 96.89% (prev 82.20%; Δ 14.69pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 60.35% (prev 32.23%; Δ 28.12pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -13.09 (EBITDA TTM -111.8m / Interest Expense TTM 11.3m) >= 6 (WARN >= 3) |
Altman Z'' -11.38
| (A) 0.34 = (Total Current Assets 379.6m - Total Current Liabilities 189.5m) / Total Assets 555.3m |
| (B) -2.70 = Retained Earnings (Balance) -1.50b / Total Assets 555.3m |
| warn (B) unusual magnitude: -2.70 — check mapping/units |
| (C) -0.27 = EBIT TTM -147.9m / Avg Total Assets 553.2m |
| (D) -2.87 = Book Value of Equity -1.50b / Total Liabilities 522.6m |
| Total Rating: -11.38 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 29.94
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield -13.55% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 11.77 = -2.50 |
| 5. Debt/Ebitda -3.45 = -2.50 |
| 6. ROIC - WACC -43.85% = -12.50 |
| 7. RoE -717.9% = -2.50 |
| 8. Rev. Trend 61.49% = 3.07 |
| 9. Rev. CAGR 31.86% = 2.50 |
| 10. EPS Trend 74.51% = 1.86 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of TVTX shares?
Over the past week, the price has changed by +8.54%, over one month by +22.26%, over three months by +56.74% and over the past year by +61.25%.
Is Travere Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TVTX is around 23.33 USD . This means that TVTX is currently overvalued and has a potential downside of 1.39%.
Is TVTX a buy, sell or hold?
- Strong Buy: 11
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TVTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 35 | 52.1% |
| Analysts Target Price | 35 | 52.1% |
| ValueRay Target Price | 25.7 | 11.6% |
Last update: 2025-09-12 04:46
TVTX Fundamental Data Overview
CCE Cash And Equivalents = 319.5m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 22.2717
P/S = 7.2915
P/B = 74.3389
Beta = 0.791
Revenue TTM = 333.9m USD
EBIT TTM = -147.9m USD
EBITDA TTM = -111.8m USD
Long Term Debt = 311.0m USD (from longTermDebt, last quarter)
Short Term Debt = 74.4m USD (from shortTermDebt, last quarter)
Debt = 385.4m USD (Calculated: Short Term 74.4m + Long Term 311.0m)
Net Debt = 324.4m USD (from netDebt column, last quarter)
Enterprise Value = 2.50b USD (2.43b + Debt 385.4m - CCE 319.5m)
Interest Coverage Ratio = -13.09 (Ebit TTM -147.9m / Interest Expense TTM 11.3m)
FCF Yield = -13.55% (FCF TTM -338.7m / Enterprise Value 2.50b)
FCF Margin = -101.4% (FCF TTM -338.7m / Revenue TTM 333.9m)
Net Margin = -50.64% (Net Income TTM -169.1m / Revenue TTM 333.9m)
Gross Margin = 96.89% ((Revenue TTM 333.9m - Cost of Revenue TTM 10.4m) / Revenue TTM)
Tobins Q-Ratio = -1.66 (set to none) (Enterprise Value 2.50b / Book Value Of Equity -1.50b)
Interest Expense / Debt = 0.74% (Interest Expense 2.85m / Debt 385.4m)
Taxrate = 21.0% (US default)
NOPAT = -147.9m (EBIT -147.9m, no tax applied on loss)
Current Ratio = 2.00 (Total Current Assets 379.6m / Total Current Liabilities 189.5m)
Debt / Equity = 11.77 (Debt 385.4m / last Quarter total Stockholder Equity 32.7m)
Debt / EBITDA = -3.45 (Net Debt 324.4m / EBITDA -111.8m)
Debt / FCF = -1.14 (Debt 385.4m / FCF TTM -338.7m)
Total Stockholder Equity = 23.5m (last 4 quarters mean)
RoA = -30.44% (Net Income -169.1m, Total Assets 555.3m )
RoE = -717.9% (Net Income TTM -169.1m / Total Stockholder Equity 23.5m)
RoCE = -44.21% (Ebit -147.9m / (Equity 23.5m + L.T.Debt 311.0m))
RoIC = -36.73% (NOPAT -147.9m / Invested Capital 402.8m)
WACC = 7.12% (E(2.43b)/V(2.82b) * Re(8.16%)) + (D(385.4m)/V(2.82b) * Rd(0.74%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 3.03%
Discount Rate = 8.16% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -338.7m)
EPS Correlation: 74.51 | EPS CAGR: 0.0% | SUE: 0.90 | # QB: True
Revenue Correlation: 61.49 | Revenue CAGR: 31.86%
Additional Sources for TVTX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle